



# Supplementary Material



**Figure S1:** Examples of positive and negative samples for each analyzed mutations. Image A, C and E correspond to positive model cases from mutation H1047R, E545K and H1047L, respectively. Images B, D and F correspond to negative cases for each mutation.



**Figure S2:** Three examples from the dilution assays' samples. Figure A I and II correspond to sample I-02 H1047R, B I and II to I-33 H1047R, C I and II to I-68 H1047L.

**Table S1.** Catalog number of QuantStudio™ 3D Digital PCR Products

Product	Catalog Identification Code
Essay E545K	Hs000000086_rm
Essay H1047R	Hs000000088_rm
<i>Essay</i> H1407L	Hs000000089_rm
Master Mix v2 (5ml)	A26359
QuantStudio™ 3D Digital PCR 20K Chip Kit v2	A26316

**Table S2.** Primers used for conventional PCR

Gene	Exon	Size (bp)	Forward Primer 5'-3'	Reverse Primer 5'-3'
PIK3CA	9	bp	CTGTGAATCCAGAGGGAAA	CTCCATTAGCACTTACCTGTGACT
	20	245 bp	GATGACATTGCATACATTG	CCTATGCAATCGGTCTTGC

bp base pairs

**Table S3:** Cycling conditions PIK3CA primers exon 20

Phase	Temperature	Time	Cycles
<b>Initial Denaturation</b>	95°C	5 minutes	1
<b>Denaturation</b>	95°C	15 seconds	
<b>Annealing</b>	55°C	30 seconds	45
<b>Extension</b>	72°C	20 seconds	
<b>Final Extension</b>	72°C	7 minutes	1
<b>Final stage</b>	10°C	5 minutes	1

**Table S4:** Cycling conditions PIK3CA primers exon 09

Phase	Temperature	Time	Cycles
<b>Initial Denaturation</b>	95°C	1 minute	1
<b>Denaturation</b>	95°C	15 seconds	
<b>Annealing</b>	53°C	15 seconds	40
<b>Extension</b>	72°C	30 seconds	
<b>Final Extension</b>	72°C	7 minutes	1
<b>Final stage</b>	4°C	5 minutes	1

**Table S5:** Mean  $\lambda$ , partition volume, total partition number and total volume of part

Template	Mutation Essay	Mean copies per partition ( $\lambda$ ) (Median)	Partition volume (nL)	Total partition number (median)	Total volume of partitions measure $\mu\text{L}$ (median)
Tumor DNA	H1047R	0.039		17084	12.90
	E545K	0.050	0.755	17065	12.88
	H1047L	0.045		17080	12.90


**Table S6:** PIK3CA H1047R mutations dilution assay by dPCR.

Sample	Theoretical Target/total (Y)	Target/Total (X)	CI Target/Total	Copies/microliter (VIC)	CI Copies/microliter (VIC)	Copies/microliter (FAM)	CI Copies/microliter (FAM)	Chips
d20R-1%	1.00%	0.82%	0.602% -- 1.123%	3692.6	3581.1 -- 3807.6	30.665	22.578 -- 41.649	1
d20R-0.10%	0.10%	0.20%	0.107% -- 0.367%	3831.8	3719.3 -- 3947.7	7.62	4.1 -- 14.161	1
d20R-0.01%	0.01%	0.12%	5.23E-2% -- 0.253%	4438.7	4306.5 -- 4574.9	5.138	2.308 -- 11.437	1

Linear Regression Output	
Observations	3
R square	1.00
Adjusted R square	0.999
Prob > F	0.014

LOD	0.04
LOQ	0.11

	coefficients	standard error	t	p	95% CI	
Variable (x)	1.428	0.032	44.841	0.014	1.024	1.833
Y intercept	-0.173	0.016	-11.022	0.058	-0.372	0.026




**Table S7:** PIK3CA H1047L mutations dilution assay by dPCR.

Sample	Theoretical Target/total (Y)	Target/Total (X)	CI Target/Total	Copies/microliter (VIC)	CI Copies/microliter (VIC)	Copies/microliter (FAM)	CI Copies/microliter (FAM)	Chips
Dl-1	1%	0.88%	0.568% -- 1.371%	1754.3	1680.7 -- 1831.2	15.641	10.09 -- 24.243	1
dl-0.1	0.10%	0.14%	4.77E-2% -- 0.419%	1727	1651.5 -- 1805.9	2.455	0.792 -- 7.612	1
dl-0.01	0.01%	0%	NA	1631.3	1561.9 -- 1703.9	0	NA	1

Linear Regression Output	
Observations	3
R square	0.996
Adjusted R square	0.991
P> F	0.042

LOD	0.11
1QO	0.34

	coefficients	standard error	t	p	95% CI	
Variable (x)	1.155	0.077	15.064	0.042	0.181	2.130000
Y intercept	-0.023	0.039	-0.577	0.667	-0.524	0.4790000




**Table S8:** PIK3CA E545K mutations dilution assay by dPCR.

Sample	Theoretical Target/total (Y)	Target/Total (X)	CI Target/Total	Copies/microliter (VIC)	CI Copies/microliter (VIC)	Copies/microliter (FAM)	CI Copies/microliter (FAM)	Chips
d9-1	1.00%	0.92%	0.758% -- 1.118%	9479.5	9268 -- 9695.9	88.261	73.395 -- 106.14	1
d9-0.1	0.10%	0.10%	5.42E-2% -- 0.177%	8792.3	8599.3 -- 8989.5	8.664	4.798 -- 15.646	1
d9-0.01	0.01%	0.03%	1.23E-2% -- 8.37E-2%	9634.7	9425.3 -- 9848.7	3.128	1.174 -- 8.335	1

Linear Regression Output	
Observations	3
R square	1.00
Adjusted R square	1.00
Prob > F	0.00891

LOD	0.02
IOQ	0.06

	coefficients	standard error	t	p	95% CI	
Variable (x)	1.106	0.013	86.891	0.007	0.944	1.268
Y intercept	-0.017	0.007	-2.521	0.240	-0.104	0.069




**Table S9:** PIK3CA mutations dilution assay by dPCR.

Sample	Theoretical Target/total (Y)	Target/Total (X)	CI Target/Total	Copies/microliter (VIC)	CI Copies/microliter (VIC)	Copies/microliter (FAM)	CI Copies/microliter (FAM)
d20R-1%	1.00%	0.82%	0.602% -- 1.123%	3692.6	3581.1 -- 3807.6	30.665	22.578 -- 41.649
d20R-0.10%	0.10%	0.20%	0.107% -- 0.367%	3831.8	3719.3 -- 3947.7	7.62	4.1 -- 14.161
d20R-0.01%	0.01%	0.12%	5.23E-2% -- 0.253%	4438.7	4306.5 -- 4574.9	5.138	2.308 -- 11.437
d9-1	1.00%	0.92%	0.758% -- 1.118%	9479.5	9268 -- 9695.9	88.261	73.395 -- 106.14
d9-0.1	0.10%	0.14%	5.42E-2% -- 0.177%	8792.3	8599.3 -- 8989.5	8.664	4.798 -- 15.646
d9-0.01	0.01%	0.03%	1.23E-2% -- 8.37E-2%	9634.7	9425.3 -- 9848.7	3.128	1.174 -- 8.335
Dl-1	1.00%	0.88%	0.568% -- 1.371%	1754.3	1680.7 -- 1831.2	15.641	10.09 -- 24.243
dl-0.1	0.10%	0.14%	4.77E-2% -- 0.419%	1727	1651.5 -- 1805.9	2.455	0.792 -- 7.612
dl-0.01	0.01%	0.00%	NA	1631.3	1561.9 -- 1703.9	0	NA

Linear Regression Output	
R square	0.986
Adjusted R square	0.984
P> F	0
observations	9

LOD	0.08
IOQ	0.23

	coefficients	standard error	t	p	95% CI	
Variable (x)	1.208	0.055	22.014	0.000	1.079	1.338
Y intercept	-0.066	0.028	-2.346	0.051	-0.133	0.001



**Table S10:** Inter-rater assay results from mutant allele frequency.

Patient sample	First Assay	Second Assay
I-02 (H1047R)	57.940%	54.300%
I-02 (H1047L)	0.065%	0.061%
I-24 (E545K)	54.590%	51.290%
I-28 (H1047L)	0.300%	0.000%
I-33 (H1047R)	0.000%	0.000%
I-35 (H1047L)	0.853%	0.807%
I-65 (H1047L)	0.000%	0.034%
I-68 (H1047R)	0.020%	0.000%
I-68 (H1047L)	0.025%	0.000%
I-70 (H1047L)	5.131%	3.402%

**Table S11:** Digital MIQE checklist for authors, reviewers and editors.

ITEM TO CHECK	IMPORTANCE	CHECKLIST
<b>EXPERIMENTAL DESIGN</b>		
Definition of experimental and control groups	E	Materials & Methods
Number within each group	E	Materials & Methods
Assay carried out by core lab or investigator's lab?	D	Core Laboratory
Power analysis	D	Not applicable
<b>SAMPLE</b>		
Description	E	Materials & Methods
Volume/mass of sample processed	D	Not applicable
Microdissection or macrodissection	E	Not applicable
Processing procedure	E	Materials & Methods
If frozen - how and how quickly?	E	Not applicable
If fixed - with what, how quickly?	E	Not available
Sample storage conditions and duration (especially for FFPE samples)	E	Materials & Methods
<b>NUCLEIC ACID EXTRACTION</b>		
Nucleic acid quantification	E	NanoDropTM Lite Spectrophotometer (ThermoFisher Scientific, Boston, MA, USA).
DNA or RNA quantification	E	DNA
Quality/Integrity, method/instrument, e.g. RNA integrity	E	Supplementary File 3
Template structural information	E	Not applicable
Template modification (digestion, sonication, preamplification etc)	E	Not applicable
Template treatment	E	Not applicable
Inhibition dilutions or spike	E	Not applicable
DNA contamination assessment of RNA samples	E	Not applicable
Details of DNase treatment where performed	E	Not applicable
Manufacturer of reagents used and catalogue number	D	Materials & Methods/Additional Files
Storage conditions (Nucleic acid): temperature, concentration, duration, buffer)	E	Materials & Methods
<b>REVERSE TRANSCRIPTION (if necessary)</b>		
cDNA priming method and concentration	E	Not applicable

One or two-step protocol	E	Not applicable
Amount of RNA used per reaction	E	Not applicable
Detailed reaction components and conditions	E	Not applicable
RT efficiency	D	Not applicable
Estimated copies measured with and without addition of RT	D	Not applicable
Manufacturer of reagents and catalogue numbers	D	Not applicable
Reaction volume	D	Not applicable
Storage conditions of cDNA	D	Not applicable
<b>dPCR TARGET INFORMATION</b>		N/A
Sequence accession number	E	Included in article
Location of amplicon	D	Not applicable
Amplicon length	E	Not applicable
In silico specificity screen (BLAST, etc)	E	Not applicable
Pseudogenes, retropseudogenes or other homologs?	D	Not applicable
Sequence alignment	D	Not applicable
Secondary structure analysis of amplicon and GC content	D	Not applicable
Location of each primer by exon or intron (if applicable)	E	Not applicable
What splice variants are targeted?	E	Not applicable
<b>dPCR OLIGONUCLEOTIDES</b>		
Primer sequences	E	Not available
RTPrimerDB Identification Number	D	Not available
Probe sequences	D	Not available
Location and identity of any modifications	E	Not available
Manufacturer of oligonucleotides	D	Not available
Purification method	D	Not available
<b>dPCR PROTOCOL</b>		Supplementary Information 2, Table S1
Complete reaction conditions	E	Materials & Methods
Reaction volume and amount of cDNA/DNA	E	Materials & Methods
Primer, (probe), Mg++ and dNTP concentrations	E	Materials & Methods
Polymerase identity and concentration	E	Materials & Methods
Buffer/kit identity and manufacturer	E	Materials & Methods/ Supplementary File 1
Exact chemical constitution of the buffer	D	Not available

Additives (SYBR Green I, DMSO, etc.)	E	Not applicable
Plates/tubes catalogue number and manufacturer	D	Materials & Methods/ Supplementary File 1
Complete thermocycling parameters	E	Materials & Methods
Reaction setup (manual/robotic)	D	Manual
Gravimetric or volumetric dilutions (manual/robotic)	D	Volumetric dilutions
Total PCR volume prepared	D	Materials & Methods
Partition number	E	Supplementary File 1
Individual partition volume	E	Supplementary File 1
Total volume of the partitions measured (effective reaction size)	E	Supplementary File 1
Partition volume variance/SD	D	Not available
Comprehensive details and appropriate use of controls	E	Materials & Methods
Manufacturer of dPCR instrument	E	Materials & Methods

#### dPCR VALIDATION

Optimisation data for the assay	D	Materials & Methods (dilution essay)
Specificity (when measuring rare mutations, pathogen sequences etc)	E	Results: ROC curve (dPCR vs Sanger sequencing)
Limit of detection of calibration control	D	Materials & Methods, Additional File
If multiplexing, comparison with singleplex assays	E	Not applicable

#### DATA ANALYSIS

Mean copies per partition ( $\lambda$ or equivalent)	E	Supplementary File 1
dPCR analysis program (source, version)	E	Available upon request
Outlier identification and disposition	E	QuantStudio 3D Analysis SuiteTM Cloud Software
Results of NTCs	E	Available upon request
Examples of positive(s) and negative experimental results as supplemental data	E	Supplementary File 3
Where appropriate, justification of number and choice of reference genes	E	Included in article
Where appropriate, description of normalization method	E	Not applicable
Number and concordance of biological replicates	D	Not applicable
Number and stage (RT or qPCR) of technical replicates	E	Not applicable
Repeatability (intra-assay variation)	E	Materials & Methods, Results and Supplementary File 3
Reproducibility (inter-assay/user/lab etc variation)	D	Not applicable

Experimental variance or CI d	E	Materials & Methods
Statistical methods for analysis	E	Materials & Methods
Data submission using RDML (Real-time PCR Data Markup Language)	D	Not applicable

---

**Essential information (E); Desirable information (D).**